Ignite Creation Date:
2024-05-05 @ 11:57 PM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01456351
Status:
COMPLETED
Last Update Posted:
2013-02-12
First Post:
2011-10-11
Brief Title:
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
Sponsor:
University of Giessen
Organization:
University of Giessen
Study Overview
Official Title:
Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study addresses the question if a therapy with bendamustine plus rituximab is comparable non inferior with the well-tried combination of fludarabine plus rituximab with regard to event free survival EFS in recurrent low malignant Non-Hodgkin and mantle cell lymphomas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None